The stock of Aligos Therapeutics Inc (ALGS) has gone up by 5.21% for the week, with a -11.79% drop in the past month and a 20.00% rise in the past quarter. The volatility ratio for the week is 9.47%, and the volatility levels for the past 30 days are 9.40% for ALGS. The simple moving average for the last 20 days is -12.13% for ALGS’s stock, with a simple moving average of 3.71% for the last 200 days.
Is It Worth Investing in Aligos Therapeutics Inc (NASDAQ: ALGS) Right Now?
ALGS has 36-month beta value of 2.35. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ALGS is 50.18M, and currently, short sellers hold a 1.73% ratio of that float. The average trading volume of ALGS on April 24, 2024 was 389.17K shares.
ALGS) stock’s latest price update
The stock price of Aligos Therapeutics Inc (NASDAQ: ALGS) has jumped by 0.53 compared to previous close of 0.82. Despite this, the company has seen a gain of 5.21% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-27 that After reaching an important support level, Aligos Therapeutics, Inc. (ALGS) could be a good stock pick from a technical perspective. ALGS recently experienced a “golden cross” event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Analysts’ Opinion of ALGS
Many brokerage firms have already submitted their reports for ALGS stocks, with Piper Sandler repeating the rating for ALGS by listing it as a “Overweight.” The predicted price for ALGS in the upcoming period, according to Piper Sandler is $3 based on the research report published on January 06, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see ALGS reach a price target of $3, previously predicting the price at $2.50. The rating they have provided for ALGS stocks is “Buy” according to the report published on January 06th, 2023.
Piper Sandler gave a rating of “Neutral” to ALGS, setting the target price at $4 in the report published on March 23rd of the previous year.
ALGS Trading at -7.46% from the 50-Day Moving Average
After a stumble in the market that brought ALGS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.00% of loss for the given period.
Volatility was left at 9.40%, however, over the last 30 days, the volatility rate increased by 9.47%, as shares sank -20.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.84% upper at present.
During the last 5 trading sessions, ALGS rose by +3.55%, which changed the moving average for the period of 200-days by -12.48% in comparison to the 20-day moving average, which settled at $0.9320. In addition, Aligos Therapeutics Inc saw 24.70% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALGS starting from Nuechterlein Carole, who purchase 7,933,601 shares at the price of $0.76 back on Oct 25 ’23. After this action, Nuechterlein Carole now owns 11,025,941 shares of Aligos Therapeutics Inc, valued at $6,004,149 using the latest closing price.
Stock Fundamentals for ALGS
Current profitability levels for the company are sitting at:
- -5.55 for the present operating margin
- 0.8 for the gross margin
The net margin for Aligos Therapeutics Inc stands at -5.65. The total capital return value is set at -0.66. Equity return is now at value -89.48, with -57.73 for asset returns.
Based on Aligos Therapeutics Inc (ALGS), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -7.09. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -85.95.
Currently, EBITDA for the company is -84.36 million with net debt to EBITDA at 1.45. When we switch over and look at the enterprise to sales, we see a ratio of -4.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.90.
Conclusion
To put it simply, Aligos Therapeutics Inc (ALGS) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
